Using Apixaban to prevent blood clots after heart attacks

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of low-dose Apixaban (2.5 mg twice daily) in preventing left ventricular thrombus formation in patients who have experienced an acute anterior myocardial infarction with severe left ventricular dysfunction. Participants will be randomly assigned to receive either Apixaban in addition to standard medical therapy or standard therapy alone. The study will follow patients for four weeks post-treatment to assess the incidence of thrombus formation. Eligible patients are those aged 18-65 with specific heart function criteria and without existing thrombus.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 18-65 years
* Presenting with acute anterior STEMI
* Severe LV dysfunction (EF\<35%) with antero-apical akinesis, dyskinesis, or aneurysm
* WIHTOUT evidence of LV thrombus.

Exclusion Criteria:

* Patients with previous anterior myocardial infarction or LAD revascularization procedures
* Patients with cardiogenic shock
* Patients with LV thrombus
* Patients with advanced CKD (Cr \> 2 and those on hemodialysis)
* Recent ICH or major bleed requiring transfusion, low platelet counts \<100,000
* History of recent CVA ( within past three months)
* Patients with atrial fibrillation or other indications for chronic anticoagulation
* Pregnant patients and those with hematological disorders

Where it's running

• NICVD Pakistan
  Karachi, Sindh, Pakistan Recruiting

Study contacts

• Principal investigator: Abdul Hakeem Professor of Cardiology, Director Cardiac Catheterization Labs, MD FACC FSCAI FASE — Nicvd
• Study coordinator: Abdul Hakeem, MD FACC FSCAI FASE
• Email: ahakeem@gmail.com
• Phone: +92 3355554342

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Apixaban vs Warfarin for a Left Ventricular Thrombus

  This study tests whether apixaban can more conveniently and safely dissolve a left ventricular blood clot compared with warfarin.

  Recruiting Phase 3 University of Arizona · Tucson, Arizona · NCT07709780

• How long-acting cabotegravir works for HIV prevention and how hormones might affect it

  This study tests whether long-acting cabotegravir can prevent HIV and how endogenous or therapeutic hormones might change its levels in blood and genital tissues among adults.

  Recruiting Phase 1 Johns Hopkins University · Baltimore, Maryland · NCT07672717

• Monitoring anti‑TFPI antibodies in adult men with severe hemophilia

  This project tests blood-based lab methods to monitor anti-TFPI antibodies in adult men with severe hemophilia who are on prophylaxis.

  Recruiting Hospices Civils de Lyon · Bron and 1 other locations · NCT07101926

• Registry for patients with left ventricular thrombus

  This study is gathering information from people with blood clots in the heart to better understand the condition and improve treatment options.

  Recruiting at 5 sites Queen Mary University of London · Cambridge, Cambridgeshire and 7 other locations · NCT06963567

• Apixaban versus warfarin for left ventricular clot after a heart attack

  This compares apixaban and warfarin to see which better clears left-ventricular blood clots in adults after a heart attack.

  Recruiting at 3 sites Phase 4 Karolinska Institutet · Falun and 15 other locations · NCT06515730

• Anticoagulation After a Heart Attack with Left Ventricular Clot

  This study tests whether adding rivaroxaban to standard dual antiplatelet therapy helps people who develop a left ventricular thrombus after a STEMI.

  Recruiting Jilin University · Changchun, Jilin · NCT05892042

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.